“Lenvatinib Is More Effective & Safer Than Sorafenib in the Treatment of Renal Cell Carcinoma - A Single-Center Retrospective Analysis of 70 Cases”. Journal of Carcinogenesis, vol. 23, no. 1, Dec. 2024, pp. 624-8, https://doi.org/10.64149/J.Carcinog.23.1.624-628.